|
Hypertrophy
Citations 181-190 of 685 total displayed.
|
Past content
(since Mar 1999):
|
- Scientific Contributions
LA419, a Novel Nitric Oxide Donor, Prevents Pathological Cardiac Remodeling in Pressure-Overloaded Rats Via Endothelial Nitric Oxide Synthase Pathway Regulation
- Gema Ruiz-Hurtado, María Fernández-Velasco, Marisabel Mourelle, and Carmen Delgado
Hypertension published November 5, 2007, doi:10.1161/HYPERTENSIONAHA.107.093666
[Abstract]
- Editorial Commentaries
Will the Lessons From Primary Aldosteronism Change the Treatment of Hypertension and Left Ventricular Hypertrophy?
- Richard J. Auchus and Mark H. Drazner
Hypertension 2007;50:837-839; published online before print as doi:10.1161/HYPERTENSIONAHA.107.097303
[Full text]
- Editorial Commentaries
Left Ventricular Hypertrophy Reversal and Prevention of Diabetes: Two Birds With One Stone?
- Giuseppe Schillaci, Matteo Pirro, and Elmo Mannarino
Hypertension 2007;50:851-853; published online before print as doi:10.1161/HYPERTENSIONAHA.107.099747
[Full text]
- Original Articles
Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism
- Cristiana Catena, GianLuca Colussi, Roberta Lapenna, Elisa Nadalini, Alessandra Chiuch, Pasquale Gianfagna, and Leonardo A. Sechi
Hypertension 2007;50:911-918; published online before print as doi:10.1161/HYPERTENSIONAHA.107.095448
[Abstract]
[Full text]
- Original Articles
Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension
- Begoña López, José M. Castellano, Arantxa González, Joaquín Barba, and Javier Díez
Hypertension 2007;50:977-983; published online before print as doi:10.1161/HYPERTENSIONAHA.107.098111
[Abstract]
[Full text]
- Original Articles
In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
- Peter M. Okin, Richard B. Devereux, Katherine E. Harris, Sverker Jern, Sverre E. Kjeldsen, Lars H. Lindholm, Björn Dahlöf for the LIFE Study Investigators
Hypertension 2007;50:984-990; published online before print as doi:10.1161/HYPERTENSIONAHA.107.096818
[Abstract]
[Full text]
- Scientific Contributions
Prevalence and Correlates of Left Ventricular Hypertrophy in the African American Study of Kidney Disease Cohort Study
- Gail E. Peterson, Tine de Backer, Avril Gabriel, Vladimir Ilic, Tudor Vagaonescu, Lawrence J. Appel, Gabriel Contreras, Cindy Kendrick, Stephen Rostand, Robert A. Phillips for the African American Study of Kidney Disease Investigators
Hypertension published October 29, 2007, doi:10.1161/HYPERTENSIONAHA.107.090613
[Abstract]
- Scientific Contributions
Synergetic Antioxidant and Vasodilatory Action of Carbon Monoxide in Angiotensin II–Induced Cardiac Hypertrophy
- Atsushi Kobayashi, Kazunobu Ishikawa, Hayato Matsumoto, Satoshi Kimura, Yoshiyuki Kamiyama, and Yukio Maruyama
Hypertension published October 8, 2007, doi:10.1161/HYPERTENSIONAHA.107.097006
[Abstract]
- Editorial Commentary
Will the Lessons From Primary Aldosteronism Change the Treatment of Hypertension and Left Ventricular Hypertrophy?
- Richard J. Auchus and Mark H. Drazner
Hypertension published October 1, 2007, doi:10.1161/HYPERTENSIONAHA.107.097303
[Abstract]
- Hypertension Highlights
Emerging Evidence for a Functional Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor Axis: More Than Regulation of Blood Pressure?
- Mark C. Chappell
Hypertension 2007;50:596-599; published online before print as doi:10.1161/HYPERTENSIONAHA.106.076216
[Full text]
|
|
